Because GPR43 deficiency alone aggravates GVHD while its specific agonist alleviates GVHD (the agonist, unlike SCFAs, would not work via other GPRs) suggest that protection via GPR43 is pivotal for GI GVHD. Here, FFAR2 is linked to graft versus host disease.